BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
我是 LongbridgeAI，我可以总结文章信息。药明生物宣布截至 4 月 30 日获得 69 个新整合项目，其中约三分之二来自欧美客户。公司维持全年营收增长 13%-17% 的指引，剔除汇率影响后预期增长 16%-20%。管理层对基于全球 CRDMO 平台及客户群扩张的增长前景保持信心，预计未来三年营收复合年增长率达 20%。
Drug development services company WuXi Biologics (Cayman) Inc. (2269.HK) announced on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients in the U.S. and Europe.
The company maintained its full-year revenue growth guidance of 13% to 17%. Excluding foreign exchange fluctuations, revenue growth is expected to range between 16% and 20%.
WuXi Biologics said it remains confident in its growth prospects, supported by its global contract research, development and manufacturing organization (CRDMO) platform and expanding customer base. Management expects revenue to achieve a compound annual growth rate of 20% over the next three years.
Manufacturing operations are expected to serve as its primary growth driver, with management forecasting a three-year growth rate of approximately 30% for the segment. As more late-stage clinical and commercial manufacturing projects advance, the company expects a growing number of manufacturing programs to generate more than $100 million in annual revenue, further boosting its scale and profitability.
WuXi Biologics shares opened higher on Monday and were trading at HK$34.22 at the midday break, up 2.64%.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here